查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1925399

客製化基因合成​​服务市场：按应用、最终用户、技术、基因长度和服务速度划分——2026-2032年全球预测

Custom Gene Synthesis Service Market by Application, End User, Technology, Gene Length, Service Speed - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 193 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，客製化基因合成​​服务市场价值将达到 12.8 亿美元，到 2026 年将成长至 14.7 亿美元，到 2032 年将达到 34.8 亿美元，复合年增长率为 15.31%。

关键市场统计数据
基准年 2025 12.8亿美元
预计年份：2026年 14.7亿美元
预测年份 2032 34.8亿美元
复合年增长率 (%) 15.31%

策略定向、品质驱动因素与采购考量：客製化基因合成​​服务如何塑造现代生物技术专案执行

本执行摘要全面概述了现代客製化基因合成​​服务及其在生物技术研发、治疗药物开发、工业生物催化、农业应用和诊断等领域的战略作用。重点阐述了核心竞争力、差异化技术方法，以及合成服务提供者如何在从概念到检验候选产品的整个创新流程中创造价值。影响采购决策和合作伙伴选择的关键因素包括对服务弹性、合成保真度和下游检验服务整合的重视程度。

新兴合成技术和不断演进的服务模式如何重塑生物技术领域的供应商差异化、客户期望和策略伙伴关係

客製化基因合成​​领域正经历着变革性的转变，这主要得益于技术的普及化、对客製化基因构建体日益增长的需求，以及供应商与终端用户之间伙伴关係的不断深化。酶促合成和微流体控合成方法的进步降低了复杂序列的进入门槛，同时提高了准确性和环境永续性。同时，将设计协助、序列检验和下游交货选项整合在一起的模组化服务模式，正在重新定义客户的期望，并促进从一次性订单向长期合作关係的转变。

评估美国关税到 2025 年的营运和策略影响，以及它们对采购方式、前置作业时间和成本可预测性的重组影响。

美国关税的累积影响将持续到2025年，为基因合成供应商及其客户带来了一系列营运和策略的考量。试剂、专用设备和某些耗材的关税正在挤压供应商的利润空间，并加剧国际供应链的摩擦，促使各方重新评估筹资策略。许多供应商和终端用户正在透过多元化采购管道、增加关键材料的储备库存以及寻找替代试剂供应商来应对，从而降低对单一供应来源的依赖风险。

按应用程式、最终用户、技术、基因长度和服务速度进行详细的細項分析，以使提供者的能力与客户价值提案相符。

細項分析揭示了需求驱动因素和服务期望的细微差别，这些差别因应用、最终用户、技术、基因长度和服务速度而异。在应用领域内，农业生物技术、诊断开发、工业生物催化、研发和治疗开发有着各自独特的需求。工业生物催化进一步细分为生质燃料生产和聚合物合成，而治疗开发则细分为抗体工程、基因治疗和疫苗开发。这些应用层面的差异决定了对规模、序列复杂性和检验严谨性的要求。在最终用户方面，学术和政府研究机构、生技公司、受託研究机构和製药公司的采用趋势各不相同，它们各自优先考虑的因素组合也不同，例如成本敏感度、法规遵循和伙伴关係深度。

区域趋势和策略采购模式正在影响美洲、欧洲、中东和非洲以及亚太地区的供应商选择和物流。

区域趋势对采购行为、监管预期和供应商网路结构有显着影响。在美洲，生物技术中心、大规模製药研发中心以及实力雄厚的风险投资支持的Start-Ups高度集中，推动了市场需求，这些企业优先考虑快速交付和一体化服务。美洲地区对本土製造能力和品质基础设施的投资，使得能够提供快速交货和强大智慧财产权保护的供应商更受青睐。欧洲、中东和非洲地区（EMEA）的特点是管理体制多样化，集中式製造能力也存在差异，客户往往更倾向于那些具备监管专业知识、本地化品管和灵活物流解决方案的供应商。

成熟供应商、专业创新者和整合商之间的竞争动态和差异化能力正在重塑服务组合和打入市场策略。

在公司层面，市场根据技术服务的能力、规模和深度进行分层。成熟的供应商利用其广泛的技术组合、经认证的品质系统和深厚的监管经验，为复杂的治疗和诊断领域的客户提供服务。同时，专业供应商则透过专注于狭窄的高价值应用或投资专有的合成化学技术和自动化来脱颖而出。新兴的Start-Ups和利基企业正透过采用酶工作流程、微流体整合和平台级改进来加速创新，从而缩短週期时间并提高序列准确性。受託研究机构(CRO) 作为整合者发挥关键作用，提供将合成与下游表征和功能测试相结合的配套服务，深受寻求单一供应商责任制的製药客户的青睐。

切实可行的策略倡议，帮助领导企业提升韧性、加快交付速度并抓住高价值机会。

产业领导者应优先采取一系列切实可行的行动，将现有能力转化为永续的优势。首先，投资于自动化和平台互通性，以缩短週期时间，并实现对各种片段长度的可预测、扩充性的交付。同时，也应增加对品质保证的投入，包括正交检验和强大的可追溯性系统，以满足治疗和诊断客户的严格要求。其次，实现供应商和试剂来源多元化，以降低关税风险和供应链脆弱性，并评估近岸外包和区域伙伴关係作为应对跨境贸易波动的策略性缓解措施。第三，制定差异化的服务层级，将快速交货服务与检验的绩效指标明确挂钩，从而在维持标准工作流程吞吐量的同时，为时间敏感型专案提供溢价。

研究采用严谨的混合方法研究途径，结合了初次访谈、技术检验、文件分析和多方相关人员检验，从而得出可靠的研究结果。

本分析的调查方法结合了定性和定量资讯来源，建构了一个稳健的、三角验证的客製化基因合成​​现状图景。主要工作包括对学术机构、生物技术公司、受託研究机构(CRO) 和製药公司的管理人员、技术总监和采购决策者进行深度访谈，以了解实际的采购标准、品质期望和服务挑战。此外，还与专家进行了技术咨询，以检验晶片合成、柱式合成、酶法合成和微流体合成等技术方法之间的差异，从而确保性能属性的准确呈现。

最终综合策略槓桿、区域考量和能力优先事项，供希望将基因合成优势转化为专案层面优势的相关人员参考。

总之，客製化基因合成​​服务在生物技术、工业、农业和诊断应用领域占据技术能力与计画成果的策略交会点。那些兼具技术广度、深厚的品质系统、以客户为中心的服务层级以及稳健的供应链策略的供应商，最有可能赢得高价值合约。到2025年，关税环境的变化使得供应来源多元化和区域生产力计画变得更加紧迫，促使买卖双方重新评估采购模式和合约风险分配。同时，按应用、最终用户、技术、基因长度和服务速度进行细分，为将供应商优势与客户需求相匹配提供了一个切实可行的蓝图，从而能够做出更精准的采购决策并製定清晰的产品蓝图。

目录

第一章：序言

第二章调查方法

  • 研究设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查前提
  • 调查限制

第三章执行摘要

  • 首席体验长观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 市场进入策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会地图
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

8. 按应用分類的客製化基因合成​​服务市场

  • 农业生物技术
  • 诊断药物研发
  • 工业生物催化剂
    • 生质燃料生产
    • 聚合物合成
  • 研究与开发
  • 治疗药物研发
    • 抗体工程
    • 基因治疗
    • 疫苗研发

9. 按最终用户分類的客製化基因合成​​服务市场

  • 学术和政府研究机构
  • 生技公司
  • CRO（受託研究机构）
  • 製药公司

10. 按技术分類的客製化基因合成​​服务市场

  • 基于晶片的合成
  • 柱层析合成
  • 酵素合成
  • 微流体控合成

11. 依基因长度分類的客製化基因合成​​服务市场

  • 长片段
  • 中型碎片
  • 短片段

12. 依服务速度分類的客製化基因合成​​服务市场

  • 表达
  • 快速交货
  • 标准

13. 各地区客製化基因合成​​服务市场

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章 按群体分類的客製化基因合成​​服务市场

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

15. 各国客製化基因合成​​服务市场

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

16. 美国客製化基因合成​​服务市场

17. 中国客製化基因合成​​服务市场

第十八章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Ansa Biotechnologies Inc.
  • ATUM
  • Azenta Life Sciences
  • Bio Basic Inc.
  • Bio-Synthesis Inc.
  • Bioneer Corporation
  • DNA Script
  • Eurofins Genomics
  • Evonetix Ltd
  • GenScript Biotech Corporation
  • Integrated DNA Technologies Inc.
  • Merck KGaA
  • OriGene Technologies Inc.
  • ProteoGenix
  • Synbio Technologies LLC
  • Telesis Bio Inc.
  • Thermo Fisher Scientific Inc.
  • Twist Bioscience Corporation
Product Code: MRR-7A380DA7C5EF

The Custom Gene Synthesis Service Market was valued at USD 1.28 billion in 2025 and is projected to grow to USD 1.47 billion in 2026, with a CAGR of 15.31%, reaching USD 3.48 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 1.28 billion
Estimated Year [2026] USD 1.47 billion
Forecast Year [2032] USD 3.48 billion
CAGR (%) 15.31%

A strategic orientation to custom gene synthesis offerings, quality levers, and procurement considerations shaping modern biotech program execution

This executive summary introduces a comprehensive view of contemporary custom gene synthesis service offerings and their strategic role across biotechnology R&D, therapeutic development, industrial biocatalysis, agricultural applications, and diagnostics. The focus is on clarifying core capabilities, differentiating technology approaches, and articulating how synthesis providers create value along the innovation pipeline from concept to validated product candidate. Emphasis is placed on service speed, synthesis fidelity, and integration of downstream validation services as principal levers that influence procurement decisions and partner selection.

The narrative also frames the interplay between rapid technological improvement and evolving regulatory expectations, highlighting that customers increasingly evaluate providers not only on price and turnaround, but on quality assurance workflows, intellectual property safeguards, and supply chain resilience. With an eye toward enterprise adoption, the introduction explains common procurement scenarios where synthesized genes drive program timelines, enable iterative design cycles, and reduce experimental uncertainty. It closes by situating the subsequent sections as an analytical progression: mapping landscape shifts, assessing tariff influences in 2025, deriving segmentation insights, and offering recommendations designed for leaders who must convert synthesis capability into competitive advantage.

How emergent synthesis technologies and evolving service models are reshaping supplier differentiation, customer expectations, and strategic partnerships across biotech

The landscape for custom gene synthesis is undergoing transformative shifts driven by technological democratization, increased demand for bespoke genetic constructs, and evolving partnerships between providers and end users. Advances in enzymatic and microfluidic synthesis methods are reducing barriers to entry for complex sequences while improving accuracy and environmental sustainability. At the same time, modular service models that bundle design support, sequence verification, and downstream delivery options are redefining customer expectations, encouraging a move from transactional orders toward long-term collaborative relationships.

Concurrently, there is a pronounced shift in customers' procurement criteria: speed tiers have crystallized into distinct service corridors with express and rapid turnaround offerings commanding strategic premium for time-sensitive programs. The growth of antibody engineering, gene therapy, and vaccine development has intensified demand for longer fragment synthesis with rigorous QC standards. In parallel, industrial biocatalyst applications such as biofuel production and polymer synthesis are pushing providers to adapt workflows for high-throughput and cost-efficient manufacturing. These changes are prompting suppliers to invest in automation, robust quality management systems, and expanded technical support capabilities, thereby catalyzing a more service-oriented ecosystem that favors depth of technical expertise and operational scalability.

Assessing the operational and strategic consequences of US tariff measures through 2025 and how they reframe sourcing, lead times, and cost predictability

The cumulative impact of United States tariffs implemented through 2025 has introduced a set of operational and strategic considerations for gene synthesis providers and their customers. Tariffs on reagents, specialized instruments, and certain consumables have compressed supplier margins and added friction to transnational supply chains, prompting reassessments of sourcing strategies. Many providers and end users have responded by diversifying procurement channels, increasing buffer inventories for critical inputs, and qualifying alternative reagent suppliers to mitigate single-source exposure.

Regulatory compliance and customs complexity have translated into longer lead times for some imported goods, encouraging nearshoring and regional sourcing where feasible. In practice, this means companies with multi-jurisdictional footprints are increasingly optimizing where they locate assembly and QC functions to avoid tariff layers while preserving access to skilled labor and infrastructure. For contract research organizations and biotechnology firms that rely on foreign-sourced instrumentation, the tariffs have elevated the importance of contractual clarity around cost escalation and delivery timelines. Ultimately, the tariff environment has accelerated strategic conversations around vertical integration, supplier consolidation, and investment in domestic production capacity to safeguard program continuity and to maintain predictable cost bases under fluctuating trade regimes.

Granular segmentation insights by application, end user, technology, gene length, and service speed to align provider capabilities with customer value propositions

Segmentation analysis reveals nuanced demand drivers and service expectations that vary substantially by application, end user, technology, gene length, and service speed. Based on Application, the market exhibits differentiated needs across Agricultural Biotechnology, Diagnostic Development, Industrial Biocatalysts, Research And Development, and Therapeutic Development, where Industrial Biocatalysts further splits into Biofuel Production and Polymer Synthesis and Therapeutic Development further divides into Antibody Engineering, Gene Therapy, and Vaccine Development; these application-level distinctions shape requirements for scale, sequence complexity, and validation rigor. Based on End User, adoption dynamics diverge among Academic And Government Research Institutes, Biotechnology Companies, Contract Research Organizations, and Pharmaceutical Companies, each of which prioritizes different combinations of cost sensitivity, regulatory compliance, and partnership depth.

Based on Technology, the competitive landscape is segmented into Chip Based Synthesis, Column Based Synthesis, Enzymatic Synthesis, and Microfluidic Synthesis, with each technology offering trade-offs in throughput, error profile, and suitability for varying fragment lengths. Based on Gene Length, service patterns separate into Long Fragment, Medium Fragment, and Short Fragment categories, which in turn influence QC protocols and delivery timelines. Finally, based on Service Speed, customers select among Express, Rapid Turnaround, and Standard options according to project urgency and budget constraints. Taken together, these segmentation axes provide a framework for providers to align technical capabilities with customer value propositions and for buyers to articulate procurement priorities that reflect application-specific risk tolerances and performance thresholds.

Regional dynamics and strategic procurement patterns across the Americas, Europe, Middle East & Africa, and Asia-Pacific shaping supplier selection and logistics

Regional dynamics exert a strong influence on procurement behavior, regulatory expectations, and the structure of supplier networks. In the Americas, demand is often driven by a concentration of biotech hubs, large pharmaceutical research centers, and robust venture-backed startups that prioritize rapid timelines and integrated service offerings. Investment in domestic production capacity and quality infrastructure in the Americas supports preferences for suppliers that can offer tight turnaround windows and strong IP protections. In Europe, Middle East & Africa, the landscape is characterized by diverse regulatory regimes and varying levels of centralized capacity, prompting customers to favor suppliers that demonstrate regulatory expertise, localized quality management, and flexible logistics solutions.

Asia-Pacific presents an expansive and heterogeneous market with a mix of well-established contract manufacturers, academic innovation centers, and rapidly growing biotech clusters. Customers in Asia-Pacific often balance cost sensitivity with accelerating demand for high-complexity constructs, which drives interest in automated synthesis platforms and scalable QC workflows. Across all regions, cross-border collaboration, regulatory harmonization efforts, and regional investments in capacity continue to influence where organizations choose to place orders, how they structure multi-supplier strategies, and the extent to which they pursue localized partnerships to reduce lead times and regulatory friction.

Competitive dynamics and capability differentiation among established providers, specialist innovators, and integrators reshaping service portfolios and go-to-market strategies

Company-level dynamics show a market stratified by capability, scale, and depth of technical services. Established suppliers often leverage broad technology portfolios, certified quality systems, and deep regulatory experience to serve complex therapeutic and diagnostic customers, while specialist providers differentiate by focusing on a narrow set of high-value applications or by investing in proprietary synthesis chemistries and automation. Emerging startups and niche players accelerate innovation by introducing enzymatic workflows, microfluidic integration, and platform-level improvements that reduce cycle times and improve sequence fidelity. Contract research organizations play a pivotal role as integrators, offering bundled services that combine synthesis with downstream characterization and functional testing, which appeals to pharmaceutical customers seeking single-vendor accountability.

Competitive dynamics also reflect different go-to-market approaches: some companies pursue volume and cost leadership by optimizing standard fragment pipelines and high-throughput operations, while others emphasize premium services such as long-fragment synthesis, bespoke sequence design, and concierge-level support. Strategic partnerships and M&A activity have concentrated capabilities in areas like antibody engineering and gene therapy, enabling larger providers to offer end-to-end solutions. Companies that succeed tend to invest in rigorous quality control, transparent traceability, and customer-facing analytics that translate technical performance into measurable program benefits for their clients.

Actionable strategic initiatives for leaders to strengthen resilience, accelerate delivery, and capture high-value opportunities through targeted investments and partnerships

Industry leaders should prioritize a set of pragmatic actions to convert capability into sustainable advantage. First, invest in automation and platform interoperability to reduce cycle times and to enable predictable, scalable delivery across a broader range of fragment lengths. This should be paired with stepped-up quality assurance investments, including orthogonal verification and robust traceability systems, to meet the stringent expectations of therapeutic and diagnostic customers. Second, diversify supplier and reagent sourcing to reduce tariff exposure and supply-chain fragility, while evaluating nearshoring or regional partnerships as strategic mitigants to cross-border trade volatility. Third, develop differentiated service tiers that clearly map express and rapid turnaround offerings to verifiable performance metrics, enabling premium pricing for time-critical programs while preserving throughput for standard workflows.

Additionally, build closer collaborations with end users through co-development programs and technical account management to embed services earlier in client development lifecycles. Expand value-added offerings such as design-for-synthesis consulting, sequence optimization, and regulatory documentation support to deepen customer stickiness. Finally, adopt transparent contracting practices that clarify responsibilities for customs, reagent substitutions, and cost escalation to minimize disputes and to maintain trust in multinational engagements. Taken together, these measures can enhance resilience, sharpen competitive positioning, and improve the ability to capture strategic, high-value engagements across applications and regions.

A rigorous mixed-methods research approach integrating primary interviews, technical validation, document synthesis, and multi-stakeholder triangulation for robust insights

The research methodology for this analysis combined qualitative and quantitative sources to build a robust, triangulated view of the custom gene synthesis landscape. Primary engagement included in-depth interviews with executives, technical leads, and procurement decision-makers across academic institutions, biotechnology companies, contract research organizations, and pharmaceutical firms to surface real-world procurement criteria, quality expectations, and service pain points. These interviews were complemented by technical consultations with subject matter experts to validate technology comparisons across chip based, column based, enzymatic, and microfluidic synthesis approaches, ensuring that performance attributes were accurately represented.

Secondary research involved a systematic review of regulatory guidance, manufacturer technical specifications, trade policy notices, and recent patent literature to capture shifts in product capabilities and trade dynamics through 2025. Data were synthesized using a framework that cross-referenced application needs with technology attributes and regional supply chain factors, while quality control steps included cross-validation with multiple industry stakeholders and iterative peer review by domain experts. This layered approach ensured that conclusions reflect operational realities, technical feasibility, and strategic implications without relying on single-source claims, thereby enhancing confidence in the report's recommendations and insights.

Final synthesis of strategic levers, regional considerations, and capability priorities for stakeholders seeking to convert gene synthesis strengths into program-level advantage

In conclusion, custom gene synthesis services occupy a strategic nexus between technological capability and program-level outcomes across biotech, industrial, agricultural, and diagnostic applications. Providers that combine technological breadth with deep quality systems, customer-centric service tiers, and resilient supply-chain strategies are best positioned to win high-value engagements. The tariff environment through 2025 has added urgency to supply diversification and regional capacity planning, encouraging both buyers and suppliers to reassess sourcing models and contractual risk allocation. Meanwhile, segmentation by application, end user, technology, gene length, and service speed provides a pragmatic blueprint for matching provider strengths to customer needs, enabling more precise procurement decisions and clearer product roadmaps.

Leaders should respond by investing strategically in automation, QC, and partnership models that embed them earlier in customer workflows, while balancing near-term operational optimizations with longer-term capability development. The recommendations and regional perspectives offered here provide a foundation for decision-makers to align investments with program priorities, reduce operational risks, and accelerate the delivery of innovation across the full lifecycle of gene-engineered products.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Custom Gene Synthesis Service Market, by Application

  • 8.1. Agricultural Biotechnology
  • 8.2. Diagnostic Development
  • 8.3. Industrial Biocatalysts
    • 8.3.1. Biofuel Production
    • 8.3.2. Polymer Synthesis
  • 8.4. Research And Development
  • 8.5. Therapeutic Development
    • 8.5.1. Antibody Engineering
    • 8.5.2. Gene Therapy
    • 8.5.3. Vaccine Development

9. Custom Gene Synthesis Service Market, by End User

  • 9.1. Academic And Government Research Institutes
  • 9.2. Biotechnology Companies
  • 9.3. Contract Research Organizations
  • 9.4. Pharmaceutical Companies

10. Custom Gene Synthesis Service Market, by Technology

  • 10.1. Chip Based Synthesis
  • 10.2. Column Based Synthesis
  • 10.3. Enzymatic Synthesis
  • 10.4. Microfluidic Synthesis

11. Custom Gene Synthesis Service Market, by Gene Length

  • 11.1. Long Fragment
  • 11.2. Medium Fragment
  • 11.3. Short Fragment

12. Custom Gene Synthesis Service Market, by Service Speed

  • 12.1. Express
  • 12.2. Rapid Turnaround
  • 12.3. Standard

13. Custom Gene Synthesis Service Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Custom Gene Synthesis Service Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Custom Gene Synthesis Service Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Custom Gene Synthesis Service Market

17. China Custom Gene Synthesis Service Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Ansa Biotechnologies Inc.
  • 18.6. ATUM
  • 18.7. Azenta Life Sciences
  • 18.8. Bio Basic Inc.
  • 18.9. Bio-Synthesis Inc.
  • 18.10. Bioneer Corporation
  • 18.11. DNA Script
  • 18.12. Eurofins Genomics
  • 18.13. Evonetix Ltd
  • 18.14. GenScript Biotech Corporation
  • 18.15. Integrated DNA Technologies Inc.
  • 18.16. Merck KGaA
  • 18.17. OriGene Technologies Inc.
  • 18.18. ProteoGenix
  • 18.19. Synbio Technologies LLC
  • 18.20. Telesis Bio Inc.
  • 18.21. Thermo Fisher Scientific Inc.
  • 18.22. Twist Bioscience Corporation

LIST OF FIGURES

  • FIGURE 1. GLOBAL CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL CUSTOM GENE SYNTHESIS SERVICE MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL CUSTOM GENE SYNTHESIS SERVICE MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY GENE LENGTH, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY SERVICE SPEED, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY AGRICULTURAL BIOTECHNOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY AGRICULTURAL BIOTECHNOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY AGRICULTURAL BIOTECHNOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY DIAGNOSTIC DEVELOPMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY DIAGNOSTIC DEVELOPMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY DIAGNOSTIC DEVELOPMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY INDUSTRIAL BIOCATALYSTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY INDUSTRIAL BIOCATALYSTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY INDUSTRIAL BIOCATALYSTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY INDUSTRIAL BIOCATALYSTS, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY BIOFUEL PRODUCTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY BIOFUEL PRODUCTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY BIOFUEL PRODUCTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY POLYMER SYNTHESIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY POLYMER SYNTHESIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY POLYMER SYNTHESIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY RESEARCH AND DEVELOPMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY RESEARCH AND DEVELOPMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY RESEARCH AND DEVELOPMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY THERAPEUTIC DEVELOPMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY THERAPEUTIC DEVELOPMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY THERAPEUTIC DEVELOPMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY THERAPEUTIC DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY ANTIBODY ENGINEERING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY ANTIBODY ENGINEERING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY ANTIBODY ENGINEERING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY GENE THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY GENE THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY GENE THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY VACCINE DEVELOPMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY VACCINE DEVELOPMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY VACCINE DEVELOPMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY ACADEMIC AND GOVERNMENT RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY ACADEMIC AND GOVERNMENT RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY ACADEMIC AND GOVERNMENT RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY CHIP BASED SYNTHESIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY CHIP BASED SYNTHESIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY CHIP BASED SYNTHESIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY COLUMN BASED SYNTHESIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY COLUMN BASED SYNTHESIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY COLUMN BASED SYNTHESIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY ENZYMATIC SYNTHESIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY ENZYMATIC SYNTHESIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY ENZYMATIC SYNTHESIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY MICROFLUIDIC SYNTHESIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY MICROFLUIDIC SYNTHESIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY MICROFLUIDIC SYNTHESIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY GENE LENGTH, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY LONG FRAGMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY LONG FRAGMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY LONG FRAGMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY MEDIUM FRAGMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY MEDIUM FRAGMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY MEDIUM FRAGMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY SHORT FRAGMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY SHORT FRAGMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY SHORT FRAGMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY SERVICE SPEED, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY EXPRESS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY EXPRESS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY EXPRESS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY RAPID TURNAROUND, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY RAPID TURNAROUND, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY RAPID TURNAROUND, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY STANDARD, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY STANDARD, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY STANDARD, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. AMERICAS CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 83. AMERICAS CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 84. AMERICAS CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY INDUSTRIAL BIOCATALYSTS, 2018-2032 (USD MILLION)
  • TABLE 85. AMERICAS CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY THERAPEUTIC DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 86. AMERICAS CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 87. AMERICAS CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 88. AMERICAS CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY GENE LENGTH, 2018-2032 (USD MILLION)
  • TABLE 89. AMERICAS CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY SERVICE SPEED, 2018-2032 (USD MILLION)
  • TABLE 90. NORTH AMERICA CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. NORTH AMERICA CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 92. NORTH AMERICA CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY INDUSTRIAL BIOCATALYSTS, 2018-2032 (USD MILLION)
  • TABLE 93. NORTH AMERICA CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY THERAPEUTIC DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 94. NORTH AMERICA CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 95. NORTH AMERICA CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 96. NORTH AMERICA CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY GENE LENGTH, 2018-2032 (USD MILLION)
  • TABLE 97. NORTH AMERICA CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY SERVICE SPEED, 2018-2032 (USD MILLION)
  • TABLE 98. LATIN AMERICA CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. LATIN AMERICA CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 100. LATIN AMERICA CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY INDUSTRIAL BIOCATALYSTS, 2018-2032 (USD MILLION)
  • TABLE 101. LATIN AMERICA CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY THERAPEUTIC DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 102. LATIN AMERICA CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 103. LATIN AMERICA CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 104. LATIN AMERICA CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY GENE LENGTH, 2018-2032 (USD MILLION)
  • TABLE 105. LATIN AMERICA CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY SERVICE SPEED, 2018-2032 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 107. EUROPE, MIDDLE EAST & AFRICA CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 108. EUROPE, MIDDLE EAST & AFRICA CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY INDUSTRIAL BIOCATALYSTS, 2018-2032 (USD MILLION)
  • TABLE 109. EUROPE, MIDDLE EAST & AFRICA CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY THERAPEUTIC DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 110. EUROPE, MIDDLE EAST & AFRICA CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPE, MIDDLE EAST & AFRICA CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPE, MIDDLE EAST & AFRICA CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY GENE LENGTH, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPE, MIDDLE EAST & AFRICA CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY SERVICE SPEED, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPE CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPE CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPE CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY INDUSTRIAL BIOCATALYSTS, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPE CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY THERAPEUTIC DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPE CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 119. EUROPE CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPE CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY GENE LENGTH, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPE CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY SERVICE SPEED, 2018-2032 (USD MILLION)
  • TABLE 122. MIDDLE EAST CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 123. MIDDLE EAST CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 124. MIDDLE EAST CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY INDUSTRIAL BIOCATALYSTS, 2018-2032 (USD MILLION)
  • TABLE 125. MIDDLE EAST CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY THERAPEUTIC DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 126. MIDDLE EAST CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 127. MIDDLE EAST CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 128. MIDDLE EAST CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY GENE LENGTH, 2018-2032 (USD MILLION)
  • TABLE 129. MIDDLE EAST CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY SERVICE SPEED, 2018-2032 (USD MILLION)
  • TABLE 130. AFRICA CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 131. AFRICA CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 132. AFRICA CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY INDUSTRIAL BIOCATALYSTS, 2018-2032 (USD MILLION)
  • TABLE 133. AFRICA CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY THERAPEUTIC DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 134. AFRICA CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 135. AFRICA CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 136. AFRICA CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY GENE LENGTH, 2018-2032 (USD MILLION)
  • TABLE 137. AFRICA CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY SERVICE SPEED, 2018-2032 (USD MILLION)
  • TABLE 138. ASIA-PACIFIC CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 139. ASIA-PACIFIC CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 140. ASIA-PACIFIC CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY INDUSTRIAL BIOCATALYSTS, 2018-2032 (USD MILLION)
  • TABLE 141. ASIA-PACIFIC CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY THERAPEUTIC DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 142. ASIA-PACIFIC CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 143. ASIA-PACIFIC CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 144. ASIA-PACIFIC CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY GENE LENGTH, 2018-2032 (USD MILLION)
  • TABLE 145. ASIA-PACIFIC CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY SERVICE SPEED, 2018-2032 (USD MILLION)
  • TABLE 146. GLOBAL CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 147. ASEAN CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 148. ASEAN CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 149. ASEAN CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY INDUSTRIAL BIOCATALYSTS, 2018-2032 (USD MILLION)
  • TABLE 150. ASEAN CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY THERAPEUTIC DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 151. ASEAN CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 152. ASEAN CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 153. ASEAN CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY GENE LENGTH, 2018-2032 (USD MILLION)
  • TABLE 154. ASEAN CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY SERVICE SPEED, 2018-2032 (USD MILLION)
  • TABLE 155. GCC CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 156. GCC CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 157. GCC CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY INDUSTRIAL BIOCATALYSTS, 2018-2032 (USD MILLION)
  • TABLE 158. GCC CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY THERAPEUTIC DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 159. GCC CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 160. GCC CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 161. GCC CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY GENE LENGTH, 2018-2032 (USD MILLION)
  • TABLE 162. GCC CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY SERVICE SPEED, 2018-2032 (USD MILLION)
  • TABLE 163. EUROPEAN UNION CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 164. EUROPEAN UNION CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 165. EUROPEAN UNION CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY INDUSTRIAL BIOCATALYSTS, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPEAN UNION CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY THERAPEUTIC DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 167. EUROPEAN UNION CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 168. EUROPEAN UNION CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPEAN UNION CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY GENE LENGTH, 2018-2032 (USD MILLION)
  • TABLE 170. EUROPEAN UNION CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY SERVICE SPEED, 2018-2032 (USD MILLION)
  • TABLE 171. BRICS CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 172. BRICS CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 173. BRICS CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY INDUSTRIAL BIOCATALYSTS, 2018-2032 (USD MILLION)
  • TABLE 174. BRICS CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY THERAPEUTIC DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 175. BRICS CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 176. BRICS CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 177. BRICS CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY GENE LENGTH, 2018-2032 (USD MILLION)
  • TABLE 178. BRICS CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY SERVICE SPEED, 2018-2032 (USD MILLION)
  • TABLE 179. G7 CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 180. G7 CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 181. G7 CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY INDUSTRIAL BIOCATALYSTS, 2018-2032 (USD MILLION)
  • TABLE 182. G7 CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY THERAPEUTIC DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 183. G7 CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 184. G7 CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 185. G7 CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY GENE LENGTH, 2018-2032 (USD MILLION)
  • TABLE 186. G7 CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY SERVICE SPEED, 2018-2032 (USD MILLION)
  • TABLE 187. NATO CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 188. NATO CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 189. NATO CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY INDUSTRIAL BIOCATALYSTS, 2018-2032 (USD MILLION)
  • TABLE 190. NATO CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY THERAPEUTIC DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 191. NATO CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 192. NATO CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 193. NATO CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY GENE LENGTH, 2018-2032 (USD MILLION)
  • TABLE 194. NATO CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY SERVICE SPEED, 2018-2032 (USD MILLION)
  • TABLE 195. GLOBAL CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 196. UNITED STATES CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 197. UNITED STATES CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 198. UNITED STATES CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY INDUSTRIAL BIOCATALYSTS, 2018-2032 (USD MILLION)
  • TABLE 199. UNITED STATES CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY THERAPEUTIC DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 200. UNITED STATES CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 201. UNITED STATES CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 202. UNITED STATES CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY GENE LENGTH, 2018-2032 (USD MILLION)
  • TABLE 203. UNITED STATES CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY SERVICE SPEED, 2018-2032 (USD MILLION)
  • TABLE 204. CHINA CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 205. CHINA CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 206. CHINA CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY INDUSTRIAL BIOCATALYSTS, 2018-2032 (USD MILLION)
  • TABLE 207. CHINA CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY THERAPEUTIC DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 208. CHINA CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 209. CHINA CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 210. CHINA CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY GENE LENGTH, 2018-2032 (USD MILLION)
  • TABLE 211. CHINA CUSTOM GENE SYNTHESIS SERVICE MARKET SIZE, BY SERVICE SPEED, 2018-2032 (USD MILLION)